Technical Analysis for OVID - Ovid Therapeutics Inc.

Grade Last Price % Change Price Change
grade F 3.19 -3.92% -0.13
OVID closed down 3.92 percent on Tuesday, December 11, 2018, on approximately normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical OVID trend table...

Date Alert Name Type % Chg
Dec 11 New 52 Week Closing Low Bearish 0.00%
Dec 11 New 52 Week Low Weakness 0.00%
Dec 11 Wide Bands Range Expansion 0.00%
Dec 11 Oversold Stochastic Weakness 0.00%
Dec 10 New 52 Week Closing Low Bearish -3.92%
Dec 10 1,2,3 Retracement Bearish Bearish Swing Setup -3.92%
Dec 10 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.92%
Dec 10 Outside Day Range Expansion -3.92%
Dec 10 Wide Bands Range Expansion -3.92%
Dec 10 Oversold Stochastic Weakness -3.92%

Older signals for OVID ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.
Is OVID a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 11.45
52 Week Low 3.1
Average Volume 85,885
200-Day Moving Average 7.2831
50-Day Moving Average 5.034
20-Day Moving Average 4.053
10-Day Moving Average 3.689
Average True Range 0.4342
ADX 32.83
+DI 9.7884
-DI 29.7223
Chandelier Exit (Long, 3 ATRs ) 4.5574
Chandelier Exit (Short, 3 ATRs ) 4.4026
Upper Bollinger Band 5.0533
Lower Bollinger Band 3.0527
Percent B (%b) 0.07
BandWidth 49.360967
MACD Line -0.5064
MACD Signal Line -0.4584
MACD Histogram -0.048
Fundamentals Value
Market Cap 78.47 Million
Num Shares 24.6 Million
EPS -4.85
Price-to-Earnings (P/E) Ratio -0.66
Price-to-Sales 0.00
Price-to-Book 1.52
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.72
Resistance 3 (R3) 3.74 3.60 3.63
Resistance 2 (R2) 3.60 3.46 3.58 3.60
Resistance 1 (R1) 3.39 3.38 3.32 3.37 3.57
Pivot Point 3.25 3.25 3.21 3.23 3.25
Support 1 (S1) 3.04 3.11 2.97 3.02 2.81
Support 2 (S2) 2.90 3.03 2.88 2.78
Support 3 (S3) 2.69 2.90 2.75
Support 4 (S4) 2.67